MediciNova Inc
NASDAQ:MNOV
Intrinsic Value
MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. [ Read More ]
The intrinsic value of one MNOV stock under the Base Case scenario is 0.23 USD. Compared to the current market price of 1.47 USD, MediciNova Inc is Overvalued by 84%.
Valuation Backtest
MediciNova Inc
Run backtest to discover the historical profit from buying and selling MNOV stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Our AI Assistant is coming soon! Stay tuned and thank you for your interest!
Provide an overview
of MediciNova Inc's business.
What risks and challenges
does MediciNova Inc face in the near future?
Summarize the latest earnings report
of MediciNova Inc.
Provide P/E
for MediciNova Inc and its competitors.
Balance Sheet Decomposition
MediciNova Inc
Current Assets | 51.2m |
Cash & Short-Term Investments | 51m |
Other Current Assets | 174.9k |
Non-Current Assets | 15.1m |
PP&E | 621.2k |
Intangibles | 14.4m |
Other Non-Current Assets | 74.2k |
Current Liabilities | 3.3m |
Accounts Payable | 1m |
Accrued Liabilities | 2.3m |
Non-Current Liabilities | 612.5k |
Other Non-Current Liabilities | 612.5k |
Earnings Waterfall
MediciNova Inc
Revenue
|
1m
USD
|
Operating Expenses
|
-10.9m
USD
|
Operating Income
|
-9.9m
USD
|
Other Expenses
|
1.3m
USD
|
Net Income
|
-8.6m
USD
|
Free Cash Flow Analysis
MediciNova Inc
What is Free Cash Flow?
MNOV Profitability Score
Profitability Due Diligence
MediciNova Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
MediciNova Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
MNOV Solvency Score
Solvency Due Diligence
MediciNova Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Score
MediciNova Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
MNOV Price Targets Summary
MediciNova Inc
Ownership
MNOV Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
MNOV Price
MediciNova Inc
Average Annual Return | -27.11% |
Standard Deviation of Annual Returns | 13.53% |
Max Drawdown | -90% |
Market Capitalization | 72.1m USD |
Shares Outstanding | 49 050 000 |
Percentage of Shares Shorted | 0.82% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. The company is headquartered in La Jolla, California and currently employs 11 full-time employees. The company went IPO on 2006-12-01. The firm is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. The company is focused on its development activities on MN-166 (ibudilast) and MN-001 (tipelukast). Its ibudilast is for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction, and prevention of acute respiratory distress syndrome. Its tipelukast is for fibrotic diseases, such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The firm's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers. Its ibudilast is in development for various neurological diseases and other diseases.
Contact
IPO
Employees
Officers
The intrinsic value of one MNOV stock under the Base Case scenario is 0.23 USD.
Compared to the current market price of 1.47 USD, MediciNova Inc is Overvalued by 84%.